Sarcopenia Treatment Market Drivers
Increasing geriatric population is expected to boost growth of the sarcopenia treatment market growth. According to the World Health Organization, by 2050, the world’s population aged 60 years and above is expected reach 2 billion from 900 million in 2015. The conferences, meetings held by the foundations help to expand and share the knowledge and information about the sarcopenia treatment which will in turn drives the growth of sarcopenia treatment market. For instance, in April 2017, the U.S. Food and Drug Administration (FDA) held its public meeting on Patient Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on symptoms and daily impacts of their condition.
Increasing investments in production of drugs and supplements are expected to boost growth of the sarcopenia treatment market. Furthermore, a growing number of pharmaceutical and food processing companies are focused on developing nutrition supplements for treatment of sarcopenia. For instance, in February 2016, Nestle announced that it has made a strategic investment for of USD 42.5 million in Pronutria Biosciences. The Nestlé’s cash will used by Pronutria Biosciences to develop a new compound called PN-107, which has the potential to tackle muscle loss caused by aging, prolonged bed rest. These factors are expected to drive growth of the sarcopenia treatment market.
Malnutrition and vitamin deficiency in developing countries is expected to boost growth of the sarcopenia treatment market. Reduction of hormone secretion rate and increasing vitamin deficiency as a result of aging are expected to create high demand for sarcopenia treatment supplements. Economic factors such as rise in consumer spending by the geriatric population, and increasing per capita healthcare expenditure are expected to drive demand for sarcopenia treatment supplements. According to the National Health Expenditure Accounts (NHEA), in 2016 the U.S. health care spending grew by 4.3%, reaching US$ 3.3 trillion or US$ 10,348 per person.
However, no new developments for the treatment of sarcopenia are also expected to hamper the market growth of sarcopenia treatment. In addition, the non-availability of new drugs is expected to hinder the sarcopenia treatment market in the upcoming years.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients